ConductScience.org, home

Paper10074911

Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.

Giatromanolaki A and 5 others. Int J Cancer, 1999. Cited by 44 papers, by iCite.

Cite this record

ConductScience Library. Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. Papers, record 10074911. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10074911

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.
PubMed
Journal
Int J Cancer
PubMed
Year
1999
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
44
iCite
Relative citation ratio, by iCite
1.22
iCite
Revised in PubMed
2019-07-08
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Giatromanolaki AA
2Koukourakis MIM I
3Georgoulias VV
4Gatter KCK C
5Harris ALA L
6Fountzilas GG

Source PubMed

Download CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Squamous CellMajor topic
Head and Neck NeoplasmsMajor topic
Neovascularization, PathologicMajor topic
Adult
Aged
Carboplatin
Cisplatin
Combined Modality Therapy
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Fluorouracil
Humans
Leucovorin
Male
Methotrexate
Middle Aged
Neoplasm Staging
Oxygen
Pilot Projects
Remission Induction
Survival Analysis
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.

PMIDTitleJournalYearIn PapersSource
20178464The role of HIF prolyl hydroxylases in tumour growth.J Cell Mol Med2010https://conductscience.org/library/papers/20178464PubMed
15256062Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.Neoplasia2004https://conductscience.org/library/papers/15256062PubMed
11742502Spontaneous and inducible apoptosis in oesophageal adenocarcinoma.Br J Cancer2001https://conductscience.org/library/papers/11742502PubMed
11448062Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.Clin Exp Metastasis2000https://conductscience.org/library/papers/11448062PubMed
11122809Clinical implications of biomarkers in head and neck cancer.Curr Oncol Rep1999https://conductscience.org/library/papers/11122809PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/10074911

GET https://conductscience.org/api/papers/v1/10074911/authors